Share ownership Kymera Therapeutics, Inc.

KYMR

US5015751044

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 20:47:32 20/05/2026 BST			5-day change	1st Jan Change
80.84 ^USD	+3.45%		-5.12%	+4.37%

05-15	Kymera Therapeutics announces presentations on KT-621, a first-in-class, oral Stat6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses	RE
05-12	Kymera Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 09:20 AM

Share class: Kymera Therapeutics, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	82,257,588	80,550,146 ( 97.92 %)	0	97.92 %

Major shareholders: Kymera Therapeutics, Inc.

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 14.33 %	11,699,950	14.33 %	949 M $
Baker Bros. Advisors LP 10.6 %	8,657,242	10.6 %	702 M $
Avoro Capital Advisor LLC 9.155 %	7,474,747	9.155 %	606 M $
T. Rowe Price International Ltd. 7.424 %	6,060,847	7.424 %	491 M $
BVF, Inc. 6.74 %	5,502,710	6.74 %	446 M $
T. Rowe Price Investment Management, Inc. 6.694 %	5,464,997	6.694 %	443 M $
T. Rowe Price Investment Management, Inc. 6.688 %	5,460,257	6.688 %	443 M $
BlackRock Advisors LLC 5.798 %	4,733,622	5.798 %	384 M $
Atlas Venture Life Science Advisors LLC 5.603 %	4,574,773	5.603 %	371 M $
Wellington Trust Co., NA 4.764 %	3,889,687	4.764 %	315 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	115.15%
Other	9.89%
State Street Corp.	2.93%
Individuals	1.55%
Merck & Co., Inc.	0.95%
Polar Capital Holdings Plc	0.26%
Manulife Financial Corp.	0.15%
Schweizerische Nationalbank	0.12%
Fifth Third Bancorp	0.06%
SEI Investments Co.	0.03%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	116.32%
United Kingdom	9.77%
Individuals	1.55%
Switzerland	1.2%
Australia	0.68%
Canada	0.66%
Luxembourg	0.25%
China	0.2%
Germany	0.14%
Taiwan	0.08%
Ireland	0.05%
Norway	0.03%
South Korea	0.03%
Puerto Rico	0.03%
Austria	0.03%
France	0.02%
Singapore	0.02%
Sweden	0.02%
Spain	0.01%

Based on 1000 largest holdings

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodyâ€™s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the bodyâ€™s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral IRF5, degrader being developed for the treatment of rheumatic and autoimmune diseases.

Employees

253

Sector

Biotechnology & Medical Research

More about the company